Abstract:Human epidemiological studies have provided compelling evidence that the risk of developing schizophrenia is significantly enhanced following prenatal and/or perinatal exposure to various environmental insults, including maternal exposure to stress, infection and/or immune activation, nutritional deficiencies and obstetric complications. Based on these associations, a great deal of interest has been centered upon the establishment of neurodevelopmental animal models which are based on prenatal and/or perinatal exposure to such environmental stimuli. In the present review, we describe this relatively novel class of epidemiology-based animal models in relation to the etiology, neurobiology and psychopharmacology of schizophrenia. Thereby, we discuss the general design and practical implementation of these models, and we provide an integrative summary of experimental findings derived from diverse epidemiology-based models, including models of maternal exposure to psychological stress, glucocorticoid treatment, viral infection, immune activating agents, protein deprivation, vitamin D deficiency, as well as models of obstetric complications in the form of birth by Caesarian section and perinatal/postnatal hypoxia. We highlight that the long-term consequences of prenatal exposure to these environmental challenges in animals successfully capture a broad spectrum of structural and functional brain abnormalities implicated in schizophrenia, some of which can be normalized by acute and/or chronic antipsychotic drug treatment. We thus conclude that epidemiology-driven neurodevelopmental models of schizophrenia are characterized by a high level of face, construct and predictive validity, including intrinsic etiological significance to the disorder. They also fulfill the expectation of the neurodevelopmental theory, such that the effects of prenatal environmental insults often only emerge after puberty. Epidemiologically based animal models not only provide indispensable experimental tools to test the hypothesis of causality in human epidemiological associations, but they also offer important new avenues for the elucidation of neurobiological, neuroendocrine and neuroimmunological mechanisms involved in the etiopathogenesis of schizophrenia and related disorders.

Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models

Rethinking Schizophrenia and Depression Comorbidity as One Psychiatric Disorder Entity: Evidence From Mouse Model

Animal Models of Maternal Immune Activation in Depression Research

What Can We Learn from Animal Models to Study Schizophrenia?

Mouse Models for Studying Depression-Like States and Antidepressant Drugs

Animal models of major depression and their clinical implications

The future of rodent models in depression research

Animal Models of Depression: What Can They Teach Us about the Human Disease?

Sleep Disturbances and Depression Are Co-morbid Conditions: Insights from Animal Models, Especially Non-human Primate Model

The recent progress in animal models of depression

Animal models of major depressive disorder and the implications for drug discovery and development

Cortical-Subcortical Interactions in Depression: From Animal Models to Human Psychopathology

Overview of Studies in Animal Models of Schizophrenia

Animal models of depression and anxiety: What do they tell us about human condition?

Animal Models of Depression: Molecular Perspectives

Dietary and metabolic risk of neuropsychiatric disorders: insights from animal models.

Animal models of major depression: drawbacks and challenges

Epidemiology-driven neurodevelopmental animal models of schizophrenia

Emotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanisms

Peering into the mind: unraveling schizophrenia's secrets using models